Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum  Ronald N. Jones, M.D., Mary.

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
Gram-positive infections: lessons learnt and novel solutions
In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria  Matthew W. Ruble, Deborah H. Gilbert, Stephen.
G. Cornaglia, A. Lönnroth, M. Struelens 
Approach to diagnosis of infective endocarditis
Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America 
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Herpes zoster in non-hospitalized children
In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin- resistant Acinetobacter baumannii  X. Vila-Farres, C. Garcia.
In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus  A. Carricajo,
Use of antimicrobials and resistance in bacteria isolated from blood cultures in a Danish county from 1992 to 1995  Thomas Lund S⊘rensen, Niels Frimodt-M⊘ller,
Clinical impact of antibiotic-resistant Gram-positive pathogens
Hydatid disease Clinical Microbiology and Infection
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on.
W. Witte, B. Pasemann, C. Cuny  Clinical Microbiology and Infection 
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species  Jacques Dubois, Claude St-Pierre  Clinical.
Structure of grepafloxacin relative to activity and safety profile
Vector control: a cornerstone in the malaria elimination campaign
Inga Odenholt, Elisabeth Löwdin, Otto Cars 
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Sofie Arens, Jan Verhaegen, Ludo Verbist 
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
Training for the infectious diseases speciality in Norway
Pharmacodynamic properties of HMR 3004, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time.
Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals  C. Nonhoff, O. Denis,
Epidemiology of opportunistic infections in AIDS patients
Laboratory diagnosis and biosafety issues of biological warfare agents
Bacterial resistance—the clinical challenge
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria  Inga Odenholt, Elisabeth Löwdin,
Sepsis and neutropenia induced by clozapine
Uncommon opportunistic fungi: new nosocomial threats
M. Aires-de-Sousa  Clinical Microbiology and Infection 
MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care.
Laboratory diagnosis of Clostridium difficile disease
Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe  Anna King, Julie Downes, Carl-Erik Nord, Ian.
Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin 
Y. Tveten, A. Jenkins, A.G. Allum, B.-E. Kristiansen 
Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union  S. Bronzwaer  Clinical.
Community-acquired pneumonia: epidemiologic and clinical consideration
Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS (T-3811) tested against non-fermentative Gram-negative bacilli  W.
P.M. Hawkey  Clinical Microbiology and Infection 
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan 
Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock.
Definition of the Clinical Antibacterial Spectrum of Activity
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party  Dilip Nathwani, Christopher Conlon  Clinical.
G.M. Rossolini, E. Mantengoli  Clinical Microbiology and Infection 
Clinical Microbiology and Infection
Overview of cefixime use in community-acquired infections
Rise and subsequent decline of community-associated methicillin resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search.
Panton–Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant Staphylococcus aureus  J.A.
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study  R. Goering, C.-E. Nord, R.
Evaluation of the BBL CrystalTM MRSA ID System for Rapid Detection of Methicillin Resistance in Staphylococcus aureus  Sylvie Dutka-Malen, Murielle Charles,
A. Manzur, F. Gudiol  Clinical Microbiology and Infection 
B.A. Cunha  Clinical Microbiology and Infection 
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group†   H. Goossens  Clinical.
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands  J.W. Mouton, A.R. Jansz  Clinical.
AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on.
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3- ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant.
Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party  Dilip Nathwani, Christopher Conlon  Clinical.
The future of diagnostic bacteriology
Presentation transcript:

Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum  Ronald N. Jones, M.D., Mary S. Barrett, B.S.  Clinical Microbiology and Infection  Volume 1, Issue 1, Pages 35-43 (September 1995) DOI: 10.1111/j.1469-0691.1995.tb00022.x Copyright © 1995 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Structure of SCH 27899. Clinical Microbiology and Infection 1995 1, 35-43DOI: (10.1111/j.1469-0691.1995.tb00022.x) Copyright © 1995 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Kill curve for S. aureus ATCC 29213 at everninomycin base concentrations of 0.5 μg/ml (MIC), 1 μg/ml (two-fold the MIC), and 4 μg/ml (eight-fold the MIC). Clinical Microbiology and Infection 1995 1, 35-43DOI: (10.1111/j.1469-0691.1995.tb00022.x) Copyright © 1995 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Kill curve for a total of four gram-positive cocci tested at 4 μg/ml everninomycin base (eight- to 16-fold the MIC). MR = methicillin-resistant and MS = methicillin-susceptible (MIC 8 ≤ μg/ml). Clinical Microbiology and Infection 1995 1, 35-43DOI: (10.1111/j.1469-0691.1995.tb00022.x) Copyright © 1995 European Society of Clinical Infectious Diseases Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.